J. Webb

First name

J.

Last name

Webb

von Arx, L. B., Rachman, J., Webb, J., Casey, C., Patel, A., Diomatari, C., et al. (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985

View

Spanopoulos, D., Okhai, H., Zaccardi, F., Tebboth, A., Barrett, B., Busse, M., et al. (2019). Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.13734

View

Spanopoulos, D., Busse, M., Webb, J., Tebboth, A., Gollop, N. D., & Marcus, M. W. (2019). DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice. Clin Ther. http://doi.org/10.1016/j.clinthera.2019.05.010

View

Webb, J., Mount, J., von Arx, L. B., Rachman, J., Spanopoulos, D., Wood, R., et al. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580

View